MDS 2021 | Novel targets in low-risk MDS
Sophie Park
• 22 Sep 2021
Sophie Park, MD, Grenoble Alpes Hospital, Grenoble, France, provides an overview of novel targets for the treatment of lower-risk myelodysplastic syndromes (MDS), highlighting use of the telomerase inhibitor imetelstat and the HIF-PH inhibitor roxadustat. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
Disclosures
Sophie Park, MD, has participated in advisory boards with Novartis, Pfizer, Takeda, and BMS/Celgene; has received research grants from Novartis, Pfizer, Takeda, BMS/Celgene and Sandoz; and has received speaker’s honoraria from Novartis, Takeda ad BMS/Celgene.
